Received Jun 5, 2026
Reports are unverified and do not show that a vaccine caused an event. Full disclaimer
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | BZ9KH | — |
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | BZ9KH | — |
Extra dose to a pregnant patient; Drug Exposure During Pregnancy; Drug Exposure During Pregnancy; This non-serious prospective pregnancy case was reported by a nurse via call center representative and described the occurrence of extra dose administered in a 39-year-old female patient who received DTPa (Reduced antigen) (Boostrix) suspension for injection in pre-filled syringe (batch number BZ9KH) for prophylaxis. On 27-MAY-2026, the patient received the 2nd dose of Boostrix. On 08-APR-2026, an unknown time after receiving Boostrix, the patient experienced vaccine exposure during pregnancy (Verbatim: Drug Exposure During Pregnancy). On 27-MAY-2026, the patient experienced extra dose administered (Verbatim: Extra dose to a pregnant patient) and vaccine exposure during pregnancy (Verbatim: Drug Exposure During Pregnancy). Pregnancy exposure: Pregnancy Exposure (Boostrix): To mother in third trimester Pregnancy Exposure (Boostrix): To mother in third trimester Estimated Delivery/Due date: 23-JUN-2026 Pregnancy Outcome: Pregnancy was ongoing This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.